Status:
UNKNOWN
Brain Metastases in Norway - A Prospective Cohort Study
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
Norwegian Cancer Society
South-Eastern Norway Regional Health Authority
Conditions:
Brain Metastases
Eligibility:
All Genders
18+ years
Brief Summary
The overall aim and primary outcome of this study will be a descriptive analysis of the current treatment practice of BM in Norway. Specifically, it may give answers to the following research question...
Eligibility Criteria
Inclusion
- Verified cancer diagnosis of solid tumors (based on radiological, histological/cytological or operative evidence).
- Brain metastases verified by computer tomography (CT), contrast-enhanced magnetic resonance imaging (MRI), or surgical biopsies
- Age ≥ 18 years
- Able to comply with study procedures
- Able to provide written informed consent after information in Norwegian
Exclusion
- Primary brain tumors
- Primary hematological malignancies (lymphomas, leukemias)
- Previous diagnosis and/or treatment of BM
- Unable to produce written informed consent after information in Norwegian
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2024
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT03346655
Start Date
January 1 2018
End Date
November 1 2024
Last Update
November 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital
Oslo, Norway